INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Northrop Grumman Corporation - NOC
Werte in diesem Artikel
NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Northrop Grumman Corporation ("Northrop Grumman" or the "Company") (NYSE: NOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Northrop Grumman and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 22, 2025, Northrop Grumman issued a press release announcing its financial results for the first quarter of 2025. Among other items, Northrop Grumman reported revenue of $9.47 billion, representing a 7% year-over-year decline and missing consensus estimates by $480 million. The Company's results included a charge of $477 million pretax tied to manufacturing updates related to its B-21 bomber program. On a related earnings call, Northrop Grumman's Chief Executive Officer attributed the "charges on the [B-21 bomber] program" largely to "inflationary factors[.]"
On this news, Northrop Grumman's stock price fell $67.25 per share, or 12.66%, to close at $464.08 per share on April 22, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-northrop-grumman-corporation---noc-302452876.html
SOURCE Pomerantz LLP
Übrigens: Northrop Grumman und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Northrop Grumman
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Northrop Grumman
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Northrop Grumman Corp.
Analysen zu Northrop Grumman Corp.
Datum | Rating | Analyst | |
---|---|---|---|
29.03.2018 | Northrop Grumman Overweight | Barclays Capital | |
26.10.2017 | Northrop Grumman Outperform | RBC Capital Markets | |
12.01.2017 | Northrop Grumman Outperform | RBC Capital Markets | |
10.11.2016 | Northrop Grumman Overweight | Barclays Capital | |
06.10.2016 | Northrop Grumman Outperform | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
29.03.2018 | Northrop Grumman Overweight | Barclays Capital | |
26.10.2017 | Northrop Grumman Outperform | RBC Capital Markets | |
12.01.2017 | Northrop Grumman Outperform | RBC Capital Markets | |
10.11.2016 | Northrop Grumman Overweight | Barclays Capital | |
06.10.2016 | Northrop Grumman Outperform | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
19.05.2016 | Northrop Grumman Sector Perform | RBC Capital Markets | |
02.05.2016 | Northrop Grumman Equal Weight | Barclays Capital | |
30.04.2015 | Northrop Grumman Neutral | UBS AG | |
12.02.2015 | Northrop Grumman Equal Weight | Barclays Capital | |
19.10.2012 | Northrop Grumman perform | Oppenheimer & Co. Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
13.09.2012 | Northrop Grumman sell | UBS AG | |
14.06.2006 | Update Northrop Grumman Corp.: Underperform | Goldman Sachs |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Northrop Grumman Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen